Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGIONASDAQ:DAWNNASDAQ:DICENASDAQ:VTYX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$32.19+1.6%$29.80$19.80▼$35.50$1.81B0.83802,785 shs333,451 shsDAWNDay One Biopharmaceuticals$13.70-9.8%$15.28$9.67▼$17.85$1.20B-1.48795,001 shs2.69 million shsDICEDICE Therapeutics$47.55$47.31$15.08▼$47.90$2.27B1.031.03 million shsN/AVTYXVentyx Biosciences$4.14-2.4%$6.03$1.87▼$40.58$291.87M0.273.63 million shs265,575 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-0.44%+9.09%+6.70%+35.23%+41.13%DAWNDay One Biopharmaceuticals-8.71%+2.29%+1.13%+11.45%+29.39%DICEDICE Therapeutics0.00%0.00%0.00%0.00%+50.19%VTYXVentyx Biosciences-2.53%-3.20%-35.17%+112.00%-88.74%Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning (Ad)Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDEMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals1.3365 of 5 stars1.32.00.04.71.20.80.0DAWNDay One Biopharmaceuticals3.3361 of 5 stars4.42.00.00.03.12.50.6DICEDICE TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVTYXVentyx Biosciences2.7224 of 5 stars3.33.00.00.01.74.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals2.50Moderate Buy$33.504.07% UpsideDAWNDay One Biopharmaceuticals2.86Moderate Buy$39.33187.10% UpsideDICEDICE Therapeutics2.22Hold$55.6717.07% UpsideVTYXVentyx Biosciences2.56Moderate Buy$21.75425.36% UpsideCurrent Analyst RatingsLatest VTYX, AGIO, DICE, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2024DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.004/24/2024DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.004/24/2024DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $33.004/22/2024DAWNDay One BiopharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$32.00 ➝ $36.004/9/2024AGIOAgios PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight3/26/2024DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$40.003/13/2024VTYXVentyx BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/12/2024VTYXVentyx BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$12.003/12/2024VTYXVentyx BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$7.00 ➝ $16.002/28/2024DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $40.002/28/2024VTYXVentyx BiosciencesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$26.82M67.44N/AN/A$14.51 per share2.22DAWNDay One BiopharmaceuticalsN/AN/AN/AN/A$3.98 per shareN/ADICEDICE Therapeutics$1.13M2,008.50N/AN/A$10.86 per share4.38VTYXVentyx BiosciencesN/AN/AN/AN/A$4.13 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$352.09M-$6.34N/AN/AN/A-1,312.64%-38.08%-33.69%5/2/2024 (Confirmed)DAWNDay One Biopharmaceuticals-$188.92M-$2.38N/AN/AN/AN/A-51.67%-48.30%5/6/2024 (Estimated)DICEDICE Therapeutics-$83.89M-$2.34N/AN/AN/AN/A-22.01%-20.79%N/AVTYXVentyx Biosciences-$192.96M-$3.30N/AN/AN/AN/A-62.58%-57.42%5/9/2024 (Estimated)Latest VTYX, AGIO, DICE, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024N/AAGIOAgios Pharmaceuticals-$1.63N/A+$1.63N/AN/AN/A 2/27/2024Q4 2023VTYXVentyx Biosciences-$0.87-$0.79+$0.08-$0.79N/AN/A2/26/2024Q4 2023DAWNDay One Biopharmaceuticals-$0.57-$0.64-$0.07-$0.64N/AN/A2/15/2024Q4 2023AGIOAgios Pharmaceuticals-$1.64-$1.72-$0.08-$1.72$7.80 million$7.10 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ADICEDICE TherapeuticsN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A12.2711.99DAWNDay One BiopharmaceuticalsN/A12.7212.72DICEDICE TherapeuticsN/A25.8832.44VTYXVentyx BiosciencesN/A11.8711.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ADAWNDay One Biopharmaceuticals87.95%DICEDICE TherapeuticsN/AVTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.24%DAWNDay One Biopharmaceuticals8.40%DICEDICE Therapeutics4.90%VTYXVentyx Biosciences24.39%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals38356.19 million53.81 millionOptionableDAWNDay One Biopharmaceuticals15587.38 million80.04 millionOptionableDICEDICE Therapeutics7147.73 million45.39 millionNot OptionableVTYXVentyx Biosciences7970.50 million53.30 millionOptionableVTYX, AGIO, DICE, and DAWN HeadlinesSourceHeadlineFINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firmaccesswire.com - April 25 at 1:30 PMInvestors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 25 at 2:35 AMInvestors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 25 at 2:35 AMShareholders of Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 24 at 2:15 PMInvestors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 24 at 2:15 PMLevi & Korsinsky Reminds Ventyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYXaccesswire.com - April 24 at 11:45 AMVentyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 24 at 11:45 AMClass Action Filed Against Ventyx Biosciences, Inc. (VTYX) - April 30, 2024 Deadline to Join - Contact Levi & Korsinskyaccesswire.com - April 24 at 8:15 AMVentyx Biosciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 24 at 8:15 AMShareholders of Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 24 at 12:30 AMApril 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYXaccesswire.com - April 24 at 12:30 AMSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firmprnewswire.com - April 23 at 11:30 PMSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firmaccesswire.com - April 23 at 6:15 PMLevi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadlineaccesswire.com - April 23 at 4:45 PMLevi & Korsinsky Reminds Ventyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYXaccesswire.com - April 23 at 4:45 PMVTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuitprnewswire.com - April 23 at 3:59 PMShareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn Moreaccesswire.com - April 23 at 2:15 PMLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYXaccesswire.com - April 23 at 11:30 AMVentyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 23 at 9:30 AMLevi & Korsinsky Reminds Ventyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYXaccesswire.com - April 23 at 9:30 AMVentyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXaccesswire.com - April 23 at 4:45 AMVTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadlineaccesswire.com - April 23 at 4:45 AMUPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firmmarkets.businessinsider.com - April 22 at 1:58 PMSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyxmarkets.businessinsider.com - April 22 at 8:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAgios PharmaceuticalsNASDAQ:AGIOAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Day One BiopharmaceuticalsNASDAQ:DAWNDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.DICE TherapeuticsNASDAQ:DICEDICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.Ventyx BiosciencesNASDAQ:VTYXVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.